-
公开(公告)号：US07501412B2
公开(公告)日：2009-03-10
申请号：US10536173
申请日：2003-11-21
申请人： Masakazu Fujio , Hiroyuki Satoh , Shinya Inoue , Toshifumi Matsumoto , Yasuhiro Egi , Taichi Takahashi
发明人： Masakazu Fujio , Hiroyuki Satoh , Shinya Inoue , Toshifumi Matsumoto , Yasuhiro Egi , Taichi Takahashi
IPC分类号： C07D403/02 , A61K31/47
CPC分类号： C07D471/04 , A61K31/472 , A61K31/4725 , A61K31/4745 , A61K31/496 , A61K31/5377 , C07D217/24 , C07D401/04 , C07D401/06 , C07D513/04
摘要： The present invention relates to an isoquinoline compound represented by the following formula (I) or (II), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction.
摘要翻译： 本发明涉及由下式（I）或（II）表示的异喹啉化合物，其光学活性形式，其药学上可接受的盐，其水加合物，其水合物及其溶剂合物，以及 用于预防和/或治疗由含有该化合物的聚（ADP-核糖）聚合酶的高反应性引起的疾病和含该化合物的聚（ADP-核糖）聚合酶抑制剂。 此外，该化合物可用作预防和/或治疗脑梗塞的药剂，特别是作为预防和/或治疗急性脑梗死的药物。
-
公开(公告)号：US20060094743A1
公开(公告)日：2006-05-04
申请号：US10536173
申请日：2003-11-21
申请人： Masakazu Fujio , Hiroyuki Satoh , Shinya Inoue , Toshifumi Matsumoto , Yasuhiro Egi , Taichi Takahashi
发明人： Masakazu Fujio , Hiroyuki Satoh , Shinya Inoue , Toshifumi Matsumoto , Yasuhiro Egi , Taichi Takahashi
IPC分类号： A61K31/4745 , A61K31/4709 , C07D471/02 , C07D403/02
CPC分类号： C07D471/04 , A61K31/472 , A61K31/4725 , A61K31/4745 , A61K31/496 , A61K31/5377 , C07D217/24 , C07D401/04 , C07D401/06 , C07D513/04
摘要： The present invention relates to an isoquinoline compound represented by the following formula (I) or (II), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction.
-
公开(公告)号：US20070161620A1
公开(公告)日：2007-07-12
申请号：US11688103
申请日：2007-03-19
IPC分类号： A61K31/55 , A61K31/496 , A61K31/4709 , C07D401/02 , C07D403/02
CPC分类号： C07D401/04 , A61K31/4725 , C07D207/12 , C07D401/06 , C07D405/06
摘要： The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.
摘要翻译： 本发明涉及由下式（I）表示的异喹啉化合物，其光学活性形式，其药学上可接受的盐，其水加合物，其水合物和溶剂化物，以及预防药物 和/或治疗由含有该化合物的聚（ADP-核糖）聚合酶和含该化合物的聚（ADP-核糖）聚合酶抑制剂）的高反应性引起的疾病。 此外，该化合物可用作预防和/或治疗脑梗塞的药剂，特别是作为预防和/或治疗急性脑梗死的药物。 此外，该化合物可用作改善与脑梗死特别是急性脑梗死相关的神经症状的预防和/或治疗剂。 其中符号与描述中定义的相同。
-
公开(公告)号：US07220759B2
公开(公告)日：2007-05-22
申请号：US10836377
申请日：2004-04-30
IPC分类号： C07D217/22 , A61K31/47
CPC分类号： C07D401/04 , A61K31/4725 , C07D207/12 , C07D401/06 , C07D405/06
摘要： The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.
摘要翻译： 本发明涉及由下式（I）表示的异喹啉化合物，其光学活性形式，其药学上可接受的盐，其水加合物，其水合物和溶剂化物，以及预防药物 和/或治疗由含有该化合物的聚（ADP-核糖）聚合酶和含该化合物的聚（ADP-核糖）聚合酶抑制剂）的高反应性引起的疾病。 此外，该化合物可用作预防和/或治疗脑梗塞的药剂，特别是作为预防和/或治疗急性脑梗死的药物。 此外，该化合物可用作改善与脑梗死特别是急性脑梗死相关的神经症状的预防和/或治疗剂。 其中符号与描述中定义的相同。
-
公开(公告)号：US07812178B2
公开(公告)日：2010-10-12
申请号：US12263963
申请日：2008-11-03
IPC分类号： C07D405/00 , C07D207/00 , C07D207/40
CPC分类号： C07D401/04 , A61K31/4725 , C07D207/12 , C07D401/06 , C07D405/06
摘要： The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.
摘要翻译： 本发明涉及由下式（I）表示的异喹啉化合物，其光学活性形式，其药学上可接受的盐，其水加合物，其水合物和溶剂化物，以及预防药物 和/或治疗由含有该化合物的聚（ADP-核糖）聚合酶和含该化合物的聚（ADP-核糖）聚合酶抑制剂）的高反应性引起的疾病。 此外，该化合物可用作预防和/或治疗脑梗塞的药剂，特别是作为预防和/或治疗急性脑梗死的药物。 此外，该化合物可用作改善与脑梗死特别是急性脑梗死相关的神经症状的预防和/或治疗剂。 其中符号与描述中定义的相同。
-
公开(公告)号：US07459465B2
公开(公告)日：2008-12-02
申请号：US11688103
申请日：2007-03-19
IPC分类号： C07D403/02 , A61K31/47
CPC分类号： C07D401/04 , A61K31/4725 , C07D207/12 , C07D401/06 , C07D405/06
摘要： The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.
摘要翻译： 本发明涉及由下式（I）表示的异喹啉化合物，其光学活性形式，其药学上可接受的盐，其水加合物，其水合物和溶剂化物，以及预防药物 和/或治疗由含有该化合物的聚（ADP-核糖）聚合酶和含该化合物的聚（ADP-核糖）聚合酶抑制剂）的高反应性引起的疾病。 此外，该化合物可用作预防和/或治疗脑梗塞的药剂，特别是作为预防和/或治疗急性脑梗死的药物。 此外，该化合物可用作改善与脑梗死特别是急性脑梗死相关的神经症状的预防和/或治疗剂。 其中符号与描述中定义的相同。
-
公开(公告)号：US20110130419A1
公开(公告)日：2011-06-02
申请号：US12672784
申请日：2008-08-08
IPC分类号： A61K31/4725 , C07D401/06 , A61P9/10
CPC分类号： C07D403/06 , C07D401/06
摘要： The invention provides a salt of (R)-3-[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]-5-methyl-2H-isoquinolin-1-one and a crystal thereof. (R)-3-[2-(2-Hydroxymethylpyrrolidin-1-yl)ethyl]-5-methyl-2H-isoquinolin-1-one monophosphate is a compound which is chemically stable, has high solubility, and shows less weight change due to humidity as compared to a free form and monohydrochloride dihydrate, and is superior as a bulk drug for pharmaceutical products.
摘要翻译： 本发明提供（R）-3- [2-（2-羟甲基吡咯烷-1-基）乙基] -5-甲基-2H-异喹啉-1-酮及其结晶的盐。 （R）-3- [2-（2-羟甲基吡咯烷-1-基）乙基] -5-甲基-2H-异喹啉-1-酮单磷酸酯是一种化学稳定的化合物，溶解度高，重量变化较小 由于与游离形式和单盐酸盐二水合物相比的湿度，并且作为药物的主要药物是优异的。
-
公开(公告)号：US08309573B2
公开(公告)日：2012-11-13
申请号：US12672784
申请日：2008-08-08
IPC分类号： A61K31/47 , C07D217/22
CPC分类号： C07D403/06 , C07D401/06
摘要： The invention provides a salt of (R)-3-[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]-5-methyl-2H-isoquinolin-1-one and a crystal thereof. (R)-3-[2-(2-Hydroxymethylpyrrolidin-1-ypethyl]-5-methyl-2H-1-isoquinolin-1-one monophosphate is a compound which is chemically stable, has high solubility, and shows less weight change due to humidity as compared to a free form and monohydrochloride dihydrate, and is superior as a bulk drug for pharmaceutical products.
摘要翻译： 本发明提供（R）-3- [2-（2-羟甲基吡咯烷-1-基）乙基] -5-甲基-2H-异喹啉-1-酮及其结晶的盐。 （R）-3- [2-（2-羟甲基吡咯烷-1-基乙基）-5-甲基-2H-1-异喹啉-1-酮单磷酸酯是一种化学稳定的化合物，溶解度高，重量变化较小 由于与游离形式和单盐酸盐二水合物相比的湿度，并且作为药物的主要药物是优异的。
-
公开(公告)号：US06468998B1
公开(公告)日：2002-10-22
申请号：US09830718
申请日：2001-05-01
IPC分类号： C07D20714
CPC分类号： C07D451/02 , C07D207/14 , C07D453/02
摘要： The present invention provides a pyrrolidine compound of the formula (I) wherein each symbol is as defined in the specification, an optically active compound thereof and a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition containing a compound of the formula (I), an optically active compound thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. The compound of the present invention has a serotonin 2 receptor antagonistic action along with a platelet aggregation suppressive action, a peripheral circulation improving action and a lacrimation promoting action. Therefore, the compound of the present invention can be a useful medicine showing effect against thrombotic embolism, dry eye and the like.
摘要翻译： 本发明提供式（I）的吡咯烷化合物，其中各符号如说明书中所定义，其光学活性化合物及其药学上可接受的盐。 本发明还提供含有式（I）化合物，其光学活性化合物或其药学上可接受的盐和药学上可接受的添加剂的药物组合物。 本发明的化合物具有5-羟色胺2受体拮抗作用以及血小板聚集抑制作用，周围循环改善作用和流泪促进作用。 因此，本发明的化合物可以是显示对血栓栓塞，干眼症等的效果的有用的药物。
-
公开(公告)号：US20120221324A1
公开(公告)日：2012-08-30
申请号：US13397497
申请日：2012-02-15
IPC分类号： G06F17/27
CPC分类号： G06F17/2785 , G06F16/3344
摘要： In a text document processing apparatus, there is provided standard knowledge network data composed of networked phrases having strong mutual relation to each other, the phrases being selected from a knowledge field including contents of a text document to be examined. In addition, there is provided a document knowledge preparing function that prepares knowledge network data of the document to be examined, the knowledge network data being composed of networked phrases having strong mutual relation to each other, the phrases being selected from the text document. Further, a processing unit that checks a specified word constituting the knowledge network data of the document to be examined and a standard knowledge network data, and in a case when information of phrases which are networked to the specified word are different from each other, outputs difference information including information of the specified word.
摘要翻译： 在文本文档处理装置中，提供由彼此之间具有强相互关系的网络短语组成的标准知识网络数据，该短语从包括要检查的文本文档的内容的知识字段中选择。 此外，提供了一种准备要检查的文档的知识网络数据的文档知识准备功能，知识网络数据由彼此之间具有强相互关系的网络短语组成，短语从文本文档中选择。 此外，检查构成待检查文档的知识网络数据的特定单词和标准知识网络数据的处理单元，并且在与指定单词联网的短语的信息彼此不同的情况下，输出 差异信息包括指定字的信息。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.037 秒)
